Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 14/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 10/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3659645 | 0.89 | OPRM1 (0.46) | OPRD1OPRM1OPRK1CHRM2CHRM3 | |
| SCHEMBL3659597 | 0.81 | CYP3A4 (0.48) | OPRD1OPRM1SIGMAR1 | |
| SCHEMBL3661017 | 0.80 | OPRD1 (0.51) | OPRD1OPRM1OPRK1CHRM2CHRM3 | |
| SCHEMBL3662547 | 0.80 | HRH3 (0.47) | OPRM1CHRM2CHRM3 | |
| SCHEMBL3665788 | 0.79 | OPRD1 (0.42) | OPRD1OPRM1OPRK1 | |
| SCHEMBL3663419 | 0.79 | DRD2 (0.47) | OPRD1OPRM1OPRK1 | |
| SCHEMBL3664394 | 0.79 | GRIN2B (0.45) | OPRD1OPRM1OPRK1CHRM3 | |
| SCHEMBL3662630 | 0.78 | UTS2R (0.48) | OPRM1SLC6A9SIGMAR1 | |
| SCHEMBL3659668 | 0.77 | KMT2A (0.51) | OPRD1OPRM1OPRK1HTR7SIGMAR1 | |
| SCHEMBL3660528 | 0.74 | KDM2B (0.44) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231601-A2 | GLYCINE TRANSPORTER-1 INHIBITORS | Amgen, Inc (US) | 2010-09-29 | — | — | EP | claimed |
| WO-2009075857-A2 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC. (US) | 2009-06-18 | — | — | WO | claimed |
| EP-2231601-B1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC (US) | 2014-06-18 | — | — | EP | disclosed |
| US-8258306-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20100298341-A1 | Glycine Transporter-1 Inhibitors | AMGEN INC. | 2010-11-25 | — | — | US | disclosed |
| EP-2231601-A2 | GLYCINE TRANSPORTER-1 INHIBITORS | Amgen, Inc (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009075857-A2 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298341-A1 | Glycine Transporter-1 Inhibitors | SLC18A2, SLC7A11, SLC6A5 | OPRD1 2137/4885OPRM1 1216/4885OPRK1 1378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.